• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腰椎融合术后骨质疏松术前治疗对再手术、并发症和医疗保健利用的影响。一项 5 年的全国数据库分析。

Impact of preoperative treatment of osteoporosis on re-operations, complications and health care utilization in patients undergoing thoraco-lumbar spine fusions. A 5-year national database analysis.

机构信息

Department of Neurosurgery, University of Louisville, 200 Abraham Flexner Hwy, Louisville, KY 40202, USA.

Evergreen Hospital Neuroscience Institute, Kirkland, WA 98034, USA.

出版信息

J Clin Neurosci. 2021 Nov;93:122-129. doi: 10.1016/j.jocn.2021.09.024. Epub 2021 Sep 17.

DOI:10.1016/j.jocn.2021.09.024
PMID:34656235
Abstract

OBJECTIVE

Identify the impact of preoperative treatment of Osteoporosis (OP) on reoperation rates, complications and healthcare utilization following thoraco-lumbar (TL) spine fusions.

MATERIALS AND METHODS

We used ICD9/10 and CPT codes to extract data from MarketScan (2000-2018). Patients were divided into two groups based on preoperative treatment of OP within one year prior to the index spinal fusion: medication (m-OP) cohort and non-medication (nm-OP) cohort. Outcomes (re-operation rates, re-admission, complications, healthcare utilization) were analyzed at 1-, 12-, 24- and 60-months.

RESULTS

Of 3606 patients, 65% (n = 2330) of patients did not receive OP medications (nm-OP). At index hospitalization, there were no difference in LOS (median nm-OP: 3 days vs. m-OP:4 days), discharge to home (nm-OP 80% vs. m-OP 75%) and complications (nm-OP 13% vs. m-OP 12%). Reoperation rates were not different among the cohorts at 1- (nm-OP 5.7% vs. m-OP 4.2%), 2- (nm-OP 9.4% vs. m-OP 7.8) and 5 years (nm-OP 16.9% vs. m-OP 14.8%). Patients in m-OP cohort incurred higher overall median payments at 1 year ($17,866 vs. $ 16,010), 2 years ($38,634 vs. $34,454) and 5 years ($94,797 vs. $91,072) compared to nm-OP cohort.

CONCLUSION

Preoperative treatment of OP had no impact on complications, LOS, discharge disposition following TL fusions at index hospitalization. Similarly, no impact of preoperative treatment was noted in terms of reoperation rates at 12-, 24- and 60 months following the index spine fusion. Patients who received preoperative treatment for OP incurred higher health care utilization at 12-, 24- and 60 months following surgery.

摘要

目的

确定术前骨质疏松(OP)治疗对胸腰椎(TL)脊柱融合术后再手术率、并发症和医疗保健利用的影响。

材料和方法

我们使用 ICD9/10 和 CPT 代码从 MarketScan(2000-2018 年)中提取数据。根据索引脊柱融合术前一年内在 OP 进行的术前治疗,将患者分为两组:药物(m-OP)组和非药物(nm-OP)组。在 1、12、24 和 60 个月时分析结果(再手术率、再入院、并发症、医疗保健利用)。

结果

在 3606 名患者中,65%(n=2330)的患者未接受 OP 药物治疗(nm-OP)。在索引住院期间, LOS(nm-OP 中位数:3 天 vs. m-OP:4 天)、出院回家(nm-OP 80% vs. m-OP 75%)和并发症(nm-OP 13% vs. m-OP 12%)无差异。在 cohorts 中,1 年(nm-OP 5.7% vs. m-OP 4.2%)、2 年(nm-OP 9.4% vs. m-OP 7.8%)和 5 年(nm-OP 16.9% vs. m-OP 14.8%)的再手术率无差异。m-OP 队列的患者在 1 年($17866 比 $16010)、2 年($38634 比 $34454)和 5 年($94797 比 $91072)的总中位数支付更高。

结论

TL 融合术前 OP 治疗对 TL 融合术后的并发症、LOS、索引住院期间的出院处置没有影响。同样,在索引脊柱融合术后 12、24 和 60 个月时,术前治疗对再手术率也没有影响。接受 OP 术前治疗的患者在手术后 12、24 和 60 个月时的医疗保健利用率更高。

相似文献

1
Impact of preoperative treatment of osteoporosis on re-operations, complications and health care utilization in patients undergoing thoraco-lumbar spine fusions. A 5-year national database analysis.胸腰椎融合术后骨质疏松术前治疗对再手术、并发症和医疗保健利用的影响。一项 5 年的全国数据库分析。
J Clin Neurosci. 2021 Nov;93:122-129. doi: 10.1016/j.jocn.2021.09.024. Epub 2021 Sep 17.
2
Factors Impacting Outcomes and Health Care Utilization in Osteoporotic Patients Undergoing Lumbar Spine Fusions: A MarketScan Database Analysis.影响骨质疏松症患者腰椎融合术后结局和医疗资源利用的因素:一项 MarketScan 数据库分析。
World Neurosurg. 2020 Sep;141:e976-e988. doi: 10.1016/j.wneu.2020.06.107. Epub 2020 Jun 22.
3
Insights into complication rates, reoperation rates, and healthcare utilization associated with use of recombinant human bone morphogenetic protein-2 in patients with spine infections.了解使用重组人骨形态发生蛋白-2 治疗脊柱感染患者的并发症发生率、再次手术率和医疗保健利用率。
Neurosurg Focus. 2019 Jan 1;46(1):E8. doi: 10.3171/2018.10.FOCUS18448.
4
Does the use of preoperative bisphosphonates in patients with osteopenia and osteoporosis affect lumbar fusion rates? Analysis from a national spine registry.术前使用双膦酸盐类药物治疗骨质疏松症和骨量减少症是否会影响腰椎融合率?来自国家脊柱登记处的分析。
Neurosurg Focus. 2020 Aug;49(2):E12. doi: 10.3171/2020.5.FOCUS20262.
5
Differences in clinical outcomes and health care utilization between octogenarians and nonagenarians following decompression for lumbar spinal stenosis. A market scan analysis.腰椎管狭窄减压术后八旬老人与九旬老人的临床结局及医疗保健利用差异:一项市场扫描分析
Clin Neurol Neurosurg. 2019 Jul;182:63-69. doi: 10.1016/j.clineuro.2019.04.031. Epub 2019 May 1.
6
Impact of Surgical Approaches on Complications, Emergency Room Admissions, and Health Care Utilization in Patients Undergoing Lumbar Fusions for Degenerative Disc Diseases: A MarketScan Database Analysis.手术方式对因退行性椎间盘疾病接受腰椎融合术患者并发症、急诊入院及医疗资源利用的影响:一项MarketScan数据库分析
World Neurosurg. 2021 Jan;145:e305-e319. doi: 10.1016/j.wneu.2020.10.048. Epub 2020 Oct 15.
7
Trends and Long-term Health Care Utilization of Computer-assisted Neuronavigation in Spine Fusions: An Exact Matched Analysis of National Administrative Database.脊柱融合中计算机辅助神经导航的趋势和长期医疗保健利用:国家行政数据库的精确匹配分析。
World Neurosurg. 2022 Oct;166:e850-e858. doi: 10.1016/j.wneu.2022.07.116. Epub 2022 Aug 6.
8
5-year reoperation rates after different types of lumbar spine surgery.不同类型腰椎手术后的5年再次手术率。
Spine (Phila Pa 1976). 1998 Apr 1;23(7):814-20. doi: 10.1097/00007632-199804010-00015.
9
Cannabis Use Disorder Trends and Health Care Utilization After Cervical and Lumbar Spine Fusions.大麻使用障碍趋势和颈椎及腰椎融合术后的医疗保健利用
Spine (Phila Pa 1976). 2024 Feb 15;49(4):E28-E45. doi: 10.1097/BRS.0000000000004874. Epub 2023 Nov 10.
10
MOS short form 36 and Oswestry Disability Index outcomes in lumbar fusion: a multicenter experience.腰椎融合术的MOS简表36和奥斯威斯利功能障碍指数结果:一项多中心经验
Spine J. 2006 Jan-Feb;6(1):21-6. doi: 10.1016/j.spinee.2005.09.004.

引用本文的文献

1
Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone Health.骨质疏松症治疗进展:关注骨合成代谢药物、二次骨折预防和围手术期骨骼健康。
Curr Osteoporos Rep. 2023 Aug;21(4):386-400. doi: 10.1007/s11914-023-00793-8. Epub 2023 Jun 8.